A pinpoint solution to cancer treatment

Cancer is responsible for more than 10 million deaths annually, making it the second most common cause of death in the world after cardiovascular diseases.¹ Cancer is also a steadily growing health concern with an expected increase in the number of cases between 2022 and 2050 of approximately 77 percent.²

Despite remarkable progress in developing new anti-cancer therapeutics, the outcome for patients with solid tumors is still unsatisfactory, in part due to challenges associated with drug delivery and uptake. To address this challenge, Fluicell and Ambusol are partnering to create a catheter device based on Fluicell’s open volume microfluidic technology to enable local delivery of anti-cancer agents directly to the cancer environment. This way, it is possible to dramatically produce higher drug concentration specifically in the tumor tissue, without producing a general increase in concentration that might damage other organs.

Thanks to Fluicell’s microfluidic recirculation technology, delivery of anti-cancer agents to the tumor environment can be combined with simultaneous removal of cellular debris and other waste materials.

Read more about our partnership with Ambusol

The partnership between Fluicell and Ambusol covers five important cancer indications: glioblastoma, prostate cancer, breast cancer, skin cancer, and pancreatic cancer. The first development target is glioblastoma (GBM), a highly aggressive form of brain cancer that affects approximately 300,000 people each year.³

Glioblastoma, also known as glioblastoma multiforme, is the most aggressive and most common form of brain cancer, representing roughly 50 percent of all malignant brain tumors. Even with treatment, the median overall survival is only approximately 15 months, with a five-year survival rate of less than five percent.^3,4

The resistance of the tumor cells to conventional therapies, paired with the brain’s susceptibility to damage from the treatment, makes glioblastoma particularly challenging to treat. Through the combination of Fluicell’s high precision recirculation technology combined with Ambusol’s innovative therapeutic solution, we are addressing both these challenges to create a new way to treat one of the most aggressive forms of cancer.